CEO D. Iain Dukes was paid $1,401,924 in fiscal year 2025 (SEC filing 0001104659-26-067945 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,401,924 D. Iain Dukes total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Ask our research desk, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| D. Iain Dukes | $539,000 | $237,375 | $86,077 | $539,472 | $0 | $0 | $0 | $1,401,924 |
| Chief Executive Officer | ||||||||
| Charles Pauza | 500,000 | 180,000 | 43,037 | 269,696 | 0 | 0 | 21,307 | 1,014,040 |
| Chief Science Officer | ||||||||
| Nikolay Savchuk | 350,000 | 126,000 | 38,256 | 220,554 | 0 | 0 | 0 | 734,810 |
| Chief Operating Officer | ||||||||
| Werner Cautreels | 166,577 | 0 | 11,356 | 118,801 | 0 | 0 | 57,163 | 353,897 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| D. Iain Dukes | $1,401,924 | — | — | — |
| Charles Pauza | 1,014,040 | — | — | — |
| Nikolay Savchuk | 734,810 | — | — | — |
| Werner Cautreels | 353,897 | 647,582 | — | ↓ −293,685 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Traws Pharma, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper TRAW reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Werner Cautreels | Option | 11,530 | 3.01 | — |
| Werner Cautreels | Option | 23,000 | 1.65 | — |
| D. Iain Dukes | Option | 33,222 | 3.01 | — |
| Werner Cautreels | Option | 19,496 | 2.33 | — |
| D. Iain Dukes | RSU | 36,943 | — | 41,476 |
| Charles Pauza | RSU | 18,471 | — | 20,872 |
| Werner Cautreels | RSU | 6,000 | — | 6,780 |
| D. Iain Dukes | Option | 31,617 | 3.01 | — |
| Charles Pauza | Option | 32,406 | 3.01 | — |
| Charles Pauza | Option | 72,832 | 2.33 | — |
| Nikolay Savchuk | Option | 13,935 | 2.33 | — |
| Nikolay Savchuk | RSU | 2,025 | — | 2,288 |
| Werner Cautreels | RSU | 4,874 | — | 5,508 |
| Charles Pauza | RSU | 2,925 | — | 3,305 |
| Nikolay Savchuk | Option | 22,435 | 3.01 | — |
| Nikolay Savchuk | RSU | 16,419 | — | 18,553 |
| D. Iain Dukes | RSU | 2,025 | — | 2,288 |
| Charles Pauza | RSU | 20,130 | — | 0 |
| Nikolay Savchuk | Option | 51,741 | 2.33 | — |
| D. Iain Dukes | Option | 147,771 | 2.33 | — |
| Charles Pauza | Option | 1,054 | 2.33 | — |
The Company's executive compensation program reflects a variable pay-for-performance philosophy, utilizing several performance measures to align executive compensation with Company performance and seeking to incentivize long-term performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jack E. StoverIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance | $196,500 | $14,346 | $130,041 | $0 | $0 | $340,887 |
| M. Teresa ShoemakerIndependent · Audit · Compensation (Chair) · Nominating and Corporate Governance | 71,500 | 14,346 | 130,041 | 0 | 0 | 215,887 |
| Trafford Clarke, Ph.DIndependent · Audit · Compensation · Nominating and Corporate Governance (Chair) | 69,500 | 14,346 | 130,041 | 0 | 0 | 213,887 |
| Werner Cautreels, Ph.DNot independent | 45,000 | 11,356 | 118,081 | 0 | 0 | 174,437 |
| John Leaman, M.DIndependent · Audit · Newly elected | 13,125 | 9,455 | 65,153 | 0 | 0 | 87,733 |
| Iain Dukes, D. PhilEmployee director | — | — | — | — | — | 0 |
| Nikolay Savchuk, Ph.DEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $28,400 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $395,625 |
| Equity awards (grant-date value) | $63,849 |
| All other compensation | $0 |
| Total cost of the board | $459,474 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Traws Pharma, Inc. | 2025 | D. Iain Dukes | $539,000 | $86,077 | $539,472 | $0 | $1,401,924 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, D. Iain Dukes | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Executive Compensation”. As printed: 1,401,924. Filing ↗machine: r1 · c41 · span 491383–491392 |
| 2 | Section 01, Charles Pauza | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Executive Compensation”. As printed: 1,014,040. Filing ↗machine: r4 · c41 · span 504388–504397 |
| 3 | Section 01, Nikolay Savchuk | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Executive Compensation”. As printed: 734,810. Filing ↗machine: r5 · c41 · span 508855–508862 |
| 4 | Section 01, Werner Cautreels | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Executive Compensation”. As printed: 353,897. Filing ↗machine: r2 · c41 · span 496122–496129 |
| 5 | Section 08, Jack E. Stover | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Director Compensation”. As printed: 340,887. Filing ↗ |
| 6 | Section 08, M. Teresa Shoemaker | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Director Compensation”. As printed: 215,887. Filing ↗ |
| 7 | Section 08, Trafford Clarke, Ph.D | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Director Compensation”. As printed: 213,887. Filing ↗ |
| 8 | Section 08, Werner Cautreels, Ph.D | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Director Compensation”. As printed: 174,437. Filing ↗ |
| 9 | Section 08, John Leaman, M.D | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Director Compensation”. As printed: 87,733. Filing ↗ |
| 10 | Section 08, Iain Dukes, D. Phil | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 08, Nikolay Savchuk, Ph.D | DEF 14A | 2026-05-29 | 0001104659-26-067945 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | — | Cash 395,625 + equity 63,849 + all other 0 = 459,474, summed across the director compensation table rows.machine: formula: Σ = 459,474 |
| 14 | Traws Pharma, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-05-29 | 0001104659-26-067945 | CEO total compensation as printed in Traws Pharma, Inc.'s own proxy. As printed: 1,401,924. Filing ↗machine: r1 · c41 · span 491383–491392 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat